Navigation Links
Compandia Announces Name Change and New Diagnostic Concept
Date:9/14/2010

Compandia Announces Name Change and New Diagnostic Concept -- NOTTINGHAM, England, September 15, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Compandia Announces Name Change and New Diagnostic Concept

 

NOTTINGHAM, England, September 15, 2010 /PRNewswire/ -- Compandia has announced a name change to CompanDX. The company is a biomarker discovery company providing services to the Pharma and Biotech sectors but increasingly, as a result of in-house R&D, is identifying biomarkers that may lead to new diagnostic services and products of its own. Andy Sutton CEO of CompanDX explained "we have grown the service side of the business over the last 9 months and are delivering biomarker discovery services to large pharma, small biotech and diagnostic companies. We and our investors have always recognised the significant upside potential in the research work we conduct with collaborators and in the laboratories of our founders, the new name reflects this activity as we start to build our IP portfolio around the signatures and biomarker panels we are developing."

CompanDX also announced the launch of its new "Time to an Event" breast cancer gene panel. CompanDX presents a plenary session today at the British Breast Cancer meeting in Nottingham describing the use of its Risk Distiller bioinformatics tools to deliver the first diagnostic that predicts time to a clinical event. CompanDX scientists have used three public datasets from different clinics to derive a 31 gene signature that predicts time to metastasis following initial surgery and biopsy. The gene signature was subsequently validated on a fourth dataset from yet another clinical centre. Across these patient cohorts the actual versus signature predicted time to metastases has a correlation of 0.86 (p< 0.0001). Furthermore CompanDX for the first time has predicted a "prospective Kaplan Meier curve" which accurately tracks the actual survival curve from the combined data. Here median time to event in the patient population was 3.5 years, this was predicted to be 3.7 years by the CompanDX gene signature with no significant differences between the actual and the CompanDX curves (p = 0.555). Andy Sutton commented "We are very excited about this study, firstly it is real world data from different labs, with no abstraction of outlying patient data. Furthermore it is a 'world first' of a totally new type of diagnostic paradigm with potential to significantly alter clinical management."

CompanDX has applied funding to validate this in the clinic and has secured collaboration with leading clinical centres in London, Nottingham, Cardiff and Holland and also industry support from a world leading diagnostics company in the development of the assay.


'/>"/>
SOURCE CompanDX
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Announces Partial Conversion of Isotechnika Debenture
2. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
3. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
4. Wintherix Announces Potent Small Molecule Wnt Activators for Bone Healing.
5. Southern Research Announces Completion of $20 Million Bond Transaction
6. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
7. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
8. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
9. RSB Spine, LLC, Announces Additional FDA Clearance for the InterPlate® L-Ti
10. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):